Evidence map›Paper›PMID 42321218›Full record

ArticleNature communications2026

Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer.

Chaitanya N Parikh, Kelly D DeMarco, Nikita Bhalerao, Hadiya K Giwa, Griffin I Kane, Ronnie W Dinnell, Boyang Ma, Haruka Mori, Meghan L Brassil, Katherine C Murphy and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Chaitanya N ParikhDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Kelly D DeMarcoDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Nikita BhaleraoDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Hadiya K GiwaDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Griffin I KaneDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Ronnie W DinnellDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.ORCID http://orcid.org/0009-0009-4209-1936
Boyang MaDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Haruka MoriDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0003-4675-9971
Meghan L BrassilDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0009-0009-4235-058X
Katherine C MurphyDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-5962-9896
Zhen ZhaoCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Calvin JohnsonDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Shriram RamaniDivision of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-6719-9005
Lin ZhouDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0003-2581-4345
Loretah ChibayaDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Youwei QiaoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Kai HuDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-6555-2581
Lihua Julie ZhuDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0001-7416-0590
Brian C LewisDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Wen XueRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-9797-8042
Jason R PitarresiDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0001-9549-4768
Prabhani U AtukoraleDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.ORCID http://orcid.org/0000-0002-8470-7235
Marcus RuscettiDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA. Marcus.Ruscetti@umassmed.edu.ORCID http://orcid.org/0000-0002-4394-2087

Funding

Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI David A Tuveson · 1987 to 2026
$118.9M
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumorsR00CA241110 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RUSCETTI, MARCUS A. · 2020 to 2022
$747k
Dissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancerR00CA252153 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI PITARRESI, JASON R. · 2022 to 2024
$747k
NCI NIH HHS P30 CA045508NCI NIH HHS R00 CA241110NCI NIH HHS R00 CA252153U.S. Department of Defense (United States Department of Defense) PA230161P1U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30CA045508U.S. Department of Health & Human Services | National Institutes of Health (NIH) R00CA241110U.S. Department of Health & Human Services | National Institutes of Health (NIH) R00CA252153
6 · The paper itself

Abstract

Immunotherapy has limited success in pancreatic ductal adenocarcinoma (PDAC) due to an immune exclusive tumor microenvironment (TME) that lacks many cytokines necessary for Natural Killer (NK) and T cell responses. Here, we design multiplexed mRNAs encoding interleukins, chemokines, and interferons as a safe and effective cytokine therapy for PDAC. Intratumoral injection of IL-12, IL-18, CCL5, CXCL10, and IFNβ mRNAs achieves robust yet transient cytokine expression, leading to NK and CD8

Indexed as

Antigens, NeoplasmCarcinoma, Pancreatic DuctalCytokinesPancreatic NeoplasmsRNA, MessengerAnimalsCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsFemaleHumansImmunotherapyKiller Cells, NaturalMiceMice, Inbred C57BLTumor MicroenvironmentAntigens, NeoplasmCytokinesRNA, Messenger

Identifiers

PMID42321218
PMCPMC13427719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.